Trial Profile
A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary) ; Beclometasone/formoterol; Tiotropium bromide
- Indications Acute asthma
- Focus Registrational; Therapeutic Use
- Acronyms TRIGGER
- Sponsors Chiesi Farmaceutici
- 24 May 2023 Results from TRIMARAN and TRIGGER, presented at the 119th International Conference of the American Thoracic Society.
- 19 Jul 2022 Results of a pooled analysis of data from two 52-week clinical trials (TRIMARAN and TRIGGER) assessed the cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium published in the Respiratory Medicine
- 19 May 2021 Results of a post-hoc analysis of the TRIMARAN and TRIGGER studies to evaluate the relationship between Persistent airflow limitation (PAL) and the risk of moderate-severe exacerbations presented at the 117th International Conference of the American Thoracic Society